<p>Madrigal Pharmaceuticals（納斯達克股票代碼：MDGL）在過去三個月內被 5 位分析師分析，揭示了從看漲到看跌的多樣化觀點。</p>
<p>下表提供了分析師最近評級的簡明概述，展示了過去 30 天情緒的變化，並與前幾個月進行比較，以提供全面的視角。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析師的 12 個月價格目標顯示，平均目標為 761.6 美元，高估計為 964.00 美元，低估計為 529.00 美元。當前平均目標較之前的 549.25 美元增加了 38.66%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1771617669_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="價格目標圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1771617669_0.png"/></p>
<h2>理解分析師評級：全面解析</h2>
<p>通過審視最近的分析師行動，我們可以洞察金融專家如何看待 Madrigal Pharmaceuticals。以下總結概述了主要分析師、他們的最新評估以及對評級和價格目標的調整。</p>
<table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexandria Hammond</td>
<td>B of A Securities</td>
<td>下調</td>
<td>中性</td>
<td>$529.00</td>
<td>$570.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>Barclays</td>
<td>宣佈</td>
<td>超配</td>
<td>$964.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>Citizens</td>
<td>上調</td>
<td>市場跑贏</td>
<td>$745.00</td>
<td>$527.00</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>上調</td>
<td>超配</td>
<td>$900.00</td>
<td>$540.00</td>
</tr>
<tr>
<td>William Woods</td>
<td>B. Riley Securities</td>
<td>上調</td>
<td>買入</td>
<td>$670.00</td>
<td>$560.00</td>
</tr>
</tbody>
</table>
<h3>關鍵洞察：</h3>
<ul>
<li><strong>行動：</strong> 分析師根據市場條件和公司表現調整他們的建議。無論是 ‘維持’、‘上調’ 還是 ‘下調’ 他們的立場，反映了他們對 Madrigal Pharmaceuticals 近期發展的反應。這些信息提供了分析師對公司當前狀態的快照。</li>
<li><strong>評級：</strong> 分析師從定性角度評估股票，評級範圍從 ‘跑贏大盤’ 到 ‘跑輸大盤’。這些評級傳達了對 Madrigal Pharmaceuticals 相對於更廣泛市場的相對錶現的預期。</li>
<li><strong>價格目標：</strong> 分析師預測價格目標的變動，提供對 Madrigal Pharmaceuticals 未來價值的估計。審視當前和之前的目標提供了分析師不斷變化的預期的洞察。</li>
</ul>
<p>理解這些分析師評估與關鍵財務指標相結合，可以為 Madrigal Pharmaceuticals 的市場地位提供有價值的洞察。保持信息靈通，做出深思熟慮的決策，參考我們的評級表。</p>
<p>隨時瞭解 Madrigal Pharmaceuticals 的分析師評級。</p>
<h2>揭示 Madrigal Pharmaceuticals 背後的故事</h2>
<p>Madrigal Pharmaceuticals Inc 是一家生物製藥公司，專注於提供針對代謝功能障礙相關脂肪肝炎（MASH）的新型治療方案，這是一種嚴重的肝臟疾病，具有很高的未滿足醫療需求，可能導致肝硬化、肝衰竭和過早死亡。該公司的藥物 Rezdiffra（resmetirom）是一種每日一次的口服肝臟靶向甲狀腺激素受體激動劑，旨在針對 MASH 的關鍵潛在原因。</p>
<h3>Madrigal Pharmaceuticals：財務表現解析</h3>
<p><strong>市值視角：</strong> 該公司的市值低於行業平均水平，表明其相對於同行的規模較小。這種定位可能受到感知增長潛力或運營規模等因素的影響。</p>
<p><strong>收入增長：</strong> Madrigal Pharmaceuticals 在過去 3 個月的收入增長顯著。截至 2025 年 9 月 30 日，該公司的收入增長率約為 <strong>362.03%</strong>。這表明公司在收入方面有了顯著增加。與競爭對手相比，該公司的增長率低於醫療保健行業的平均水平。</p>
<p><strong>淨利潤率：</strong> Madrigal Pharmaceuticals 的淨利潤率超過行業標準，突顯了公司的卓越財務表現。公司實現了 <strong>-39.75%</strong> 的淨利潤率，有效管理成本並實現強勁的盈利能力。</p>
<p><strong>股本回報率（ROE）：</strong> Madrigal Pharmaceuticals 的 ROE 低於行業標準，表明在有效利用股本方面存在困難。ROE 為 <strong>-17.28%</strong>，公司可能面臨為股東提供滿意回報的挑戰。</p>
<p><strong>資產回報率（ROA）：</strong> Madrigal Pharmaceuticals 的 ROA 低於行業平均水平，表明在有效利用資產方面可能存在挑戰。ROA 為 <strong>-9.6%</strong>，公司可能面臨實現最佳財務回報的障礙。</p>
<p><strong>債務管理：</strong> Madrigal Pharmaceuticals 的債務與股本比率顯著高於行業平均水平。該比率為 <strong>0.55</strong>，表明公司在借款方面依賴較大，顯示出較高的財務風險。</p>
<h2>分析師評級的核心：每位投資者應知曉的事項</h2>
<p>銀行和金融系統的專家，分析師專注於特定股票或定義的行業進行報告。他們的全面研究包括參加公司電話會議和會議，分析財務報表，並與內部人士互動，以生成所謂的股票分析師評級。通常，分析師每季度評估和評級每隻股票一次。</p>
<p>一些分析師發佈他們對增長預期、收益和收入等指標的預測，以便為他們的評級提供額外的指導。在使用分析師評級時，重要的是要記住，股票和行業分析師也是人，他們只是向投資者提供自己的意見。</p>
<p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>

基因改革 ETF - ARK

醫療業 ETF - Vanguard

紐交所高增長板生物技術指數 ETF - First Trust

<p>Madrigal Pharmaceuticals（納斯達克代碼：MDGL）在過去三個月內獲得了 5 位分析師的混合評級，12 個月的平均目標價為 761.6 美元，比 549.25 美元上漲了 38.66%。最近的行動包括美銀證券將其評級下調至中性，以及巴克萊和派珀·桑德勒將其評級上調至增持。該公司專注於代謝功能障礙相關性脂肪肝炎的治療，顯示出 362.03% 的顯著收入增長，但面臨着股本回報率和資產回報率低的挑戰。分析師的評級反映了他們基於市場條件和公司表現不斷變化的預期</p>

<p>Madrigal Pharmaceuticals (NASDAQ: MDGL) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>Madrigal Pharmaceuticals（納斯達克股票代碼：MDGL）在過去三個月內被 5 位分析師分析，揭示了從看漲到看跌的多樣化觀點。</p>
</div><p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<div class="lb-trans"><p>下表提供了分析師最近評級的簡明概述，展示了過去 30 天情緒的變化，並與前幾個月進行比較，以提供全面的視角。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $761.6, a high estimate of $964.00, and a low estimate of $529.00. This current average has increased by 38.66% from the previous average price target of $549.25.</p>
<div class="lb-trans"><p>分析師的 12 個月價格目標顯示，平均目標為 761.6 美元，高估計為 964.00 美元，低估計為 529.00 美元。當前平均目標較之前的 549.25 美元增加了 38.66%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1771617669_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1771617669_0.png"/></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<div class="lb-trans"><h2>理解分析師評級：全面解析</h2>
</div><p>In examining recent analyst actions, we gain insights into how financial experts perceive Madrigal Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通過審視最近的分析師行動，我們可以洞察金融專家如何看待 Madrigal Pharmaceuticals。以下總結概述了主要分析師、他們的最新評估以及對評級和價格目標的調整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexandria Hammond</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$529.00</td>
<td>$570.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$964.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>Citizens</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$745.00</td>
<td>$527.00</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$900.00</td>
<td>$540.00</td>
</tr>
<tr>
<td>William Woods</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$670.00</td>
<td>$560.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexandria Hammond</td>
<td>B of A Securities</td>
<td>下調</td>
<td>中性</td>
<td>$529.00</td>
<td>$570.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>Barclays</td>
<td>宣佈</td>
<td>超配</td>
<td>$964.00</td>
<td>-</td>
</tr>
<tr>
<td>Jonathan Wolleben</td>
<td>Citizens</td>
<td>上調</td>
<td>市場跑贏</td>
<td>$745.00</td>
<td>$527.00</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>上調</td>
<td>超配</td>
<td>$900.00</td>
<td>$540.00</td>
</tr>
<tr>
<td>William Woods</td>
<td>B. Riley Securities</td>
<td>上調</td>
<td>買入</td>
<td>$670.00</td>
<td>$560.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>關鍵洞察：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Madrigal Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Madrigal Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Madrigal Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>行動：</strong> 分析師根據市場條件和公司表現調整他們的建議。無論是 ‘維持’、‘上調’ 還是 ‘下調’ 他們的立場，反映了他們對 Madrigal Pharmaceuticals 近期發展的反應。這些信息提供了分析師對公司當前狀態的快照。</li>
<li><strong>評級：</strong> 分析師從定性角度評估股票，評級範圍從 ‘跑贏大盤’ 到 ‘跑輸大盤’。這些評級傳達了對 Madrigal Pharmaceuticals 相對於更廣泛市場的相對錶現的預期。</li>
<li><strong>價格目標：</strong> 分析師預測價格目標的變動，提供對 Madrigal Pharmaceuticals 未來價值的估計。審視當前和之前的目標提供了分析師不斷變化的預期的洞察。</li>
</ul>
</div><p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Madrigal Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<div class="lb-trans"><p>理解這些分析師評估與關鍵財務指標相結合，可以為 Madrigal Pharmaceuticals 的市場地位提供有價值的洞察。保持信息靈通，做出深思熟慮的決策，參考我們的評級表。</p>
</div><p>Stay up to date on Madrigal Pharmaceuticals analyst ratings.</p>
<div class="lb-trans"><p>隨時瞭解 Madrigal Pharmaceuticals 的分析師評級。</p>
</div><h2>Unveiling the Story Behind Madrigal Pharmaceuticals</h2>
<div class="lb-trans"><h2>揭示 Madrigal Pharmaceuticals 背後的故事</h2>
</div><p>Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.</p>
<div class="lb-trans"><p>Madrigal Pharmaceuticals Inc 是一家生物製藥公司，專注於提供針對代謝功能障礙相關脂肪肝炎（MASH）的新型治療方案，這是一種嚴重的肝臟疾病，具有很高的未滿足醫療需求，可能導致肝硬化、肝衰竭和過早死亡。該公司的藥物 Rezdiffra（resmetirom）是一種每日一次的口服肝臟靶向甲狀腺激素受體激動劑，旨在針對 MASH 的關鍵潛在原因。</p>
</div><h3>Madrigal Pharmaceuticals: Financial Performance Dissected</h3>
<div class="lb-trans"><h3>Madrigal Pharmaceuticals：財務表現解析</h3>
</div><p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<div class="lb-trans"><p><strong>市值視角：</strong> 該公司的市值低於行業平均水平，表明其相對於同行的規模較小。這種定位可能受到感知增長潛力或運營規模等因素的影響。</p>
</div><p><strong>Revenue Growth:</strong> Madrigal Pharmaceuticals's revenue growth over a period of 3M has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately <strong>362.03%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增長：</strong> Madrigal Pharmaceuticals 在過去 3 個月的收入增長顯著。截至 2025 年 9 月 30 日，該公司的收入增長率約為 <strong>362.03%</strong>。這表明公司在收入方面有了顯著增加。與競爭對手相比，該公司的增長率低於醫療保健行業的平均水平。</p>
</div><p><strong>Net Margin:</strong> Madrigal Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-39.75%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> Madrigal Pharmaceuticals 的淨利潤率超過行業標準，突顯了公司的卓越財務表現。公司實現了 <strong>-39.75%</strong> 的淨利潤率，有效管理成本並實現強勁的盈利能力。</p>
</div><p><strong>Return on Equity (ROE):</strong> Madrigal Pharmaceuticals's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-17.28%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> Madrigal Pharmaceuticals 的 ROE 低於行業標準，表明在有效利用股本方面存在困難。ROE 為 <strong>-17.28%</strong>，公司可能面臨為股東提供滿意回報的挑戰。</p>
</div><p><strong>Return on Assets (ROA):</strong> Madrigal Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-9.6%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> Madrigal Pharmaceuticals 的 ROA 低於行業平均水平，表明在有效利用資產方面可能存在挑戰。ROA 為 <strong>-9.6%</strong>，公司可能面臨實現最佳財務回報的障礙。</p>
</div><p><strong>Debt Management:</strong> Madrigal Pharmaceuticals's debt-to-equity ratio is notably higher than the industry average. With a ratio of <strong>0.55</strong>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> Madrigal Pharmaceuticals 的債務與股本比率顯著高於行業平均水平。該比率為 <strong>0.55</strong>，表明公司在借款方面依賴較大，顯示出較高的財務風險。</p>
</div><h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<div class="lb-trans"><h2>分析師評級的核心：每位投資者應知曉的事項</h2>
</div><p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<div class="lb-trans"><p>銀行和金融系統的專家，分析師專注於特定股票或定義的行業進行報告。他們的全面研究包括參加公司電話會議和會議，分析財務報表，並與內部人士互動，以生成所謂的股票分析師評級。通常，分析師每季度評估和評級每隻股票一次。</p>
</div><p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<div class="lb-trans"><p>一些分析師發佈他們對增長預期、收益和收入等指標的預測，以便為他們的評級提供額外的指導。在使用分析師評級時，重要的是要記住，股票和行業分析師也是人，他們只是向投資者提供自己的意見。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>
</div>

Madrigal 製藥股票：深入探討分析師觀點（5 個評級）